Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Teens who have parental permission to drink are more likely to develop unhealthy relationships with alcohol as adults, a ...

Study finds letting teens drink at home may lead to heavier alcohol use 03:59. Some parents might think that letting their ...

(HealthDay News) — Low-dose semaglutide seems to reduce craving and certain drinking outcomes in alcohol use disorder (AUD), according to a study published online Feb. 12 in JAMA Psychiatry.

Excessive alcohol consumption is a significant public health concern, responsible for approximately 6% of all deaths and ...

Semaglutide shows promise in reducing alcohol cravings and consumption. Could it be a future treatment for AUD?

Learn how the Doomsday Clock serves as a potential indicator for health crises, including substance use disorders and Alzheimer's.

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Semaglutide may help reduce alcohol cravings and intake, according to a clinical trial. Participants receiving the drug drank ...

SALT LAKE CITY — Advocacy groups are asking parents to talk to their kids about underage drinking ahead of spring break. The ...